TY - T1的机械循环支持耐火心原性休克由于流感病毒相关心肌炎JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00925 -2020欧元SP - 2000925 AU Sieweke Jan-Thorben盟——类似,主任Muharrem盟——Stetskamp塞巴斯蒂安盟——项目部基督教非盟- Jonigk,丹尼盟——Flierl Ulrike AU -菲,托拜厄斯乔纳森•AU -赫希Valentin盟——Dutzmann Jochen AU - Hoeper,马吕斯m . AU -库恩,基督教非盟- Bauersachs,摘要N2 -背景在流感相关心肌炎合并难治性心源性休克(rCS)患者中，缺乏机械循环支持(MCS)的证据。我们试图研究MCS使用静脉-动脉体外膜氧合(VA-ECMO)和微轴流泵对rCS合并流感相关心肌炎的影响。方法这是一项前瞻性和观察性分析，来自汉诺威单中心心脏卸载登记(HACURE)在最近两个流感流行季节。我们分析了经证实的流感病毒感染相关心肌炎合并rCS的患者在MCS上入住我们的ICU。随后，我们对急性心肌梗死合并rCS和非缺血性心肌病相关rCS的患者进行倾向性评分匹配分析。结果我们描述了7例rCS合并流感相关心肌炎的患者(平均年龄:56±10岁，58%男性，流感a /B n=2/5)。没有病人在流感季节之前接种过疫苗。MCS由VA-ECMO和Impella联合提供。在2例院外心脏骤停患者中，应用VA-ECMO进行体外心肺复苏。所有患者在入院后18天内死亡。基于倾向性评分的比较与心肌梗死或非缺血性心肌病相关rCS合并MCS的患者，流感相关rCS的30天死亡率显著更高。结论:尽管rCS合并流感相关心肌炎的患者使用联合MCS可初步稳定休克，但不利的休克过程无法停止，所有患者均死亡。 Potentially, influenza virus infection critically affects other organs besides the heart leading to irreversible end-organ damage, which MCS cannot compensate and, therefore, resulted in a devastating outcome.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Sieweke reports other from ABIOMED, outside the submitted work.Conflict of interest: Dr. Akin has nothing to disclose.Conflict of interest: Mr. Stetskamp has nothing to disclose.Conflict of interest: Dr. Riehle reports other from Abiomed, outside the submitted work.Conflict of interest: Dr. Jonigk has nothing to disclose.Conflict of interest: Dr. Flierl has nothing to disclose.Conflict of interest: Dr. Pfeffer has nothing to disclose.Conflict of interest: Dr. Hirsch has nothing to disclose.Conflict of interest: Dr. Dutzmann has nothing to disclose.Conflict of interest: Dr. Höper reports personal fees from Actelion, Bayer, MSD, and Pfizer, outside the submitted work.Conflict of interest: Dr. Kühn has nothing to disclose.Conflict of interest: Dr. Bauersachs reports personal fees from Novartis, personal fees from BMS, personal fees from Pfizer, grants and personal fees from Vifor, personal fees from Bayer, personal fees from Servier, grants and personal fees from CvRX, personal fees from MSD, personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, grants and personal fees from Abiomed, personal fees from Abbott, personal fees from Medtronic, personal fees from Daiichi Sankyo, grants and personal fees from Zoll, outside the submitted work.Conflict of interest: Dr. Schäfer reports grants and personal fees from Abiomed, during the conduct of the study. ER -